NCT02044653 - Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD) | Biotech Hunter

Enrollment

257

Participants

Timeline

Start Date

April 15, 2014

Primary Completion Date

April 20, 2017

Study Completion Date

April 20, 2017

Conditions

AnemiaChronic Kidney Disease

Interventions

DRUG

GX-E2

Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

DRUG

GX-E2

Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg

DRUG

GX-E2

Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg

DRUG

NESP

Each Group of Hemodialysis (n=30) will be administered NESP 30ug

DRUG

MIRCERA

Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg

Trial Locations (5)

Bucheon St. Mary's Hospital, Bucheon-si

Bundang Seoul National University College of Medicine, Gumi

The Catholic University of Korea Incheon St.Mary's Hospital, Incheon

Gangnam severance hospital, Seoul

Seoul St.Mary's Hospital, Seoul